Understand the source comparison
Comparison of Growth Hormone Secretagogues in Research Applications
Selecting the right secretagogue depends on study design, endpoints, and tolerance for hormonal cross-reactivity. The table below summarizes the functional distinctions between ipamorelin and commonly used alternatives based on published pharmacological profil
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Selecting the right secretagogue depends on study design, endpoints, and tolerance for hormonal cross-reactivity. The table below summarizes the functional distinctions between ipamorelin and commonly used alternatives based on published pharmacological profiles.
- Ipamorelin
- 13-fold above baseline (human)
- None
- ~2 hours
- Selective GH studies, body composition, synergistic protocols with CJC-1295
- Most selective option. Ideal when cortisol or prolactin interference would confound results
- GHRP-2
- 15-fold above baseline
- Moderate (30-50% increase)
- Moderate (40-60% increase)
- Appetite research, ghrelin pathway studies
- Stronger GH response but hormonal cross-reactivity limits use in metabolic or endocrine studies
- GHRP-6
- 12-fold above baseline
- Mild (10-20% increase)
- Significant (50-70% increase)
- Appetite stimulation, ghrelin mimetic research
- High prolactin response makes it unsuitable for studies involving reproductive or metabolic endpoints
- Hexarelin
- 18-fold above baseline
- Mild
- Significant
- Cardiovascular research, neuroprotection
- Most potent GH release but desensitization occurs with chronic dosing
- MK-677
- Sustained 50-90% GH elevation
- 24 hours
- Chronic GH elevation studies, aging research, appetite modulation
- Oral bioavailable but continuous elevation disrupts pulsatile rhythm and increases insulin resistance risk
- Sermorelin
- 8-10 fold above baseline
- ~10 minutes
- GHRH receptor studies, pediatric GH deficiency models
- Extremely short half-life requires continuous infusion or multiple daily doses
- Ipamorelin's selectivity becomes a decisive factor in multi-arm studies. If a protocol involves metabolic endpoints like insulin sensitivity, cortisol elevation from GHRP-2 would introduce a confounding variable. Cortisol promotes hepatic gluconeogenesis and impairs insulin receptor signaling. Similarly, prolactin elevation affects dopamine signaling, gonadotropin release, and adipocyte metabolism, none of which should vary if growth hormone is the isolated variable. Ipamorelin removes those confounders.
- Hexarelin produces the highest peak GH response but loses efficacy after 4-6 weeks of daily administration due to receptor desensitization. This makes it suitable for acute-phase studies or short-duration interventions but problematic for chronic designs. In our experience supplying peptides for longitudinal body composition research, ipamorelin's maintained potency over 12-16 weeks consistently outperforms hexarelin in study completion rates. Researchers don't have to redesign protocols mid-study when the compound stops working.
- MK-677 occupies a distinct niche. As an oral ghrelin mimetic with a 24-hour half-life, it produces sustained GH elevation rather than pulsatile release. This flattens the natural circadian rhythm of growth hormone secretion, which peaks during slow-wave sleep and drops during waking hours. Some aging studies prefer this profile, hypothesizing that sustained elevation better mimics youthful GH patterns. However, chronic MK-677 administration is associated with insulin resistance and elevated fasting glucose in multiple trials. A side effect not observed with ipamorelin. For studies where glucose metabolism is a measured endpoint, ipamorelin is the safer choice.